Evaluation of solid free-form fabrication-based scaffolds seeded with osteoblasts and human umbilical vein endothelial cells for use in vivo osteogenesis.
Kim JY., Jin GZ., Park IS., Kim JN., Chun SY., Park EK.
Animal Study, published in Tissue Eng Part A (2010) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Tissue Eng Part A (2010)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 20163199
- DOI
- 10.1089/ten.TEA.2009.0644
- Citations
- 34
Abstract (original English)
We investigated the feasibility of using solid free-form fabrication (SFF)-based scaffolds seeded with osteoblasts, derived from human adipose-derived stem cells, and human umbilical vein endothelial cells (HUVECs) to enhance osteogenesis. To accomplish this goal, SFF-based polycaprolactone/poly-lactic-co-glycolic acid/tricalcium phosphate scaffolds were fabricated using a multihead deposition system, which is one SFF technique. The blended polycaprolactone/poly-lactic-co-glycolic acid/TCP scaffolds were seeded with human osteoblasts and HUVECs and implanted into calvaria defects in rats. At 8 and 12 weeks after implantation, microcomputed tomography, real-time polymerase chain reaction, and histological assays (hematoxylin and eosin staining and Alizarin red staining) were conducted to determine the effects of SFF-based scaffolds on osteogenic potential. In vivo experiments indicated that the osteoblast-only and osteoblast-HUVEC group produced bone formation. Additionally, scaffolds in the osteoblast-HUVEC group had the largest area of new bone tissue. Therefore, we demonstrated through microcomputed tomography and histological assays that scaffolds seeded with both human osteoblasts and HUVECs were superior to other groups for effective bone formation.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.